The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

respectively sold under the brand names Zepbound and Mounjaro for weight loss and T2D. Novo Nordisk won the race as the first US Food and Drug Administration (FDA)-approved GLP-1RA with Ozempic in ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.